Low expression of the PPARγ-regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low expression of the PPARγ-regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases
Authors
Keywords
-
Journal
Scientific Reports
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-12
DOI
10.1038/s41598-021-86329-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of thioredoxin system in cancer: strategy for cancer therapy
- (2019) Jin-Jing Jia et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma
- (2018) Ruixia Huang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP
- (2018) Lance Thielen et al. Current Opinion in Endocrinology Diabetes and Obesity
- Induction of paracrine signaling in metastatic melanoma cells by PPARγ agonist rosiglitazone activates stromal cells and enhances tumor growth
- (2018) Christine Pich et al. CANCER RESEARCH
- The Janus face of rosiglitazone
- (2018) Christine Pich et al. Oncotarget
- Editor’s Highlight: PPARβ/δ and PPARγ Inhibit Melanoma Tumorigenicity by Modulating Inflammation and Apoptosis
- (2017) Michael G. Borland et al. TOXICOLOGICAL SCIENCES
- The Leloir Pathway of Galactose Metabolism – A Novel Therapeutic Target for Hepatocellular Carcinoma
- (2016) MANSHU TANG et al. ANTICANCER RESEARCH
- Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the ‘future’ in dermatology therapeutics?
- (2015) Mrinal Gupta et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Gaining momentum: New options and opportunities for the treatment of advanced melanoma
- (2015) Olivier Michielin et al. CANCER TREATMENT REVIEWS
- Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
- (2015) Lawrence N. Kwong et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
- (2015) Alexander Meves et al. JOURNAL OF CLINICAL ONCOLOGY
- MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer
- (2015) De Chen et al. Oncotarget
- Chemotherapy and Chemoprevention by Thiazolidinediones
- (2015) Eleonore Fröhlich et al. Biomed Research International
- Thioredoxin/Txnip: Redoxisome, as a Redox Switch for the Pathogenesis of Diseases
- (2014) Eiji Yoshihara et al. Frontiers in Immunology
- Thioredoxin and Thioredoxin Target Proteins: From Molecular Mechanisms to Functional Significance
- (2012) Samuel Lee et al. ANTIOXIDANTS & REDOX SIGNALING
- Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer
- (2012) Jianbiao Zhou et al. MITOCHONDRION
- Thiazolidinediones and PPARγ agonists: time for a reassessment
- (2012) Bertrand Cariou et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
- (2009) M. A. Davies et al. CLINICAL CANCER RESEARCH
- VDUP1 mediates nuclear export of HIF1α via CRM1-dependent pathway
- (2007) Daesung Shin et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More